GenSight Biologics
105 articles about GenSight Biologics
-
GenSight Biologics Announces Additional Promising Results Of Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON)
6/8/2016
-
GenSight Biologics Closes $36 Million Series B Funding Round
7/23/2015
-
GenSight Biologics Appoints Thomas Gidoin As Chief Financial Officer & Michael Wyzga To Board Of Directors
7/7/2015
-
Eye Sees More Gene Therapy: GenSight Biologics Files For A $100 Million IPO
7/7/2015
-
GenSight Biologics, Pixium Vision And Fondation Voir Et Entendre Join Forces And Benefit From A Total € 18.5 Million Funding For SIGHT AGAIN As Part Of The Investment For The Future
1/7/2015